期刊文献+

盐酸伊立替康纳米粒的制备及体外评价 被引量:6

Preparation and in vitro evaluation of nanoparticles of irinotecan hydrochloride
原文传递
导出
摘要 目的:制备盐酸伊立替康纳米粒,并对其纳米粒形态、粒径、包封率和释放进行评价。方法:采用沉淀法制备盐酸伊立替康纳米粒,以包封率作为考察指标,筛选最优处方。用透射电镜观察纳米粒形态,激光粒径测定仪测定粒径,凝胶过滤法测定药物的包封率,透析法考察体外释药特质。结果:盐酸伊立替康纳米粒形态规整,几呈球形,强度径为(193.5±2.5)nm,载药量为26.35%,包封率为(98.00±0.01)%,体外24h的累积释放率为62.09%,比水溶液释放慢。结论:通过优化处方和工艺,制备出的盐酸伊立替康纳米粒粒径均匀,包封率较高,体外释药具有缓释特点。 OBJECTIVE To prepare nanoparticles of irinotecan hydrochloride(CPT-11 NPS)and to evaluate their particle size,morphology,encapsulation efficiency and release characteristics.METHODS CPT-11 NPS were prepared by precipitation.The encapsulated ratio was used as an estimated parameter in order to select one of the most appropriate formulations The morphology of CPT-11 NPS was characterized by transmission electron microscopy.The particle size was measured by laser granularity analyzer.The encapsulation efficiency was determined by Sephadex G-50 gel chromatography.Dialysis was applied to investigate the release of CPT-11 NPS.RESULTS The prepared CPT-11 NPS were spherical with intensity diameter of(193.5±2.5) nm.The drug loading capacity and encapsulation efficiency were 26.35% and(98±0.01)%,respectively.The cumulative release amount reached 62.09% of CPT-11 NPS during 24 h,and CPT-11 NPS released CPT-11much more slowly compared with aqueous irinotecan hydrochloride solution.CONCLUSION The particle size of the CPT-11 NPS prepared by the use of this optimized formulation is uniform,the encapsulation efficiency is high and CPT-11 NPS have extended-release features.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2012年第21期1723-1726,共4页 Chinese Journal of Hospital Pharmacy
关键词 盐酸伊立替康 纳米粒 沉淀法 包封率 体外释药 irinotecan hydrochloride nanoparticles precipitation methods encapsulation efficiency in vitro release
  • 相关文献

参考文献18

  • 1孙晓东,岳树香,李建伟.盐酸伊立替康临床应用研究进展[J].中国药业,2011,20(14):79-80. 被引量:14
  • 2张亮..伊立替康阳离子肺靶向脂质体注射剂的制备工艺及体内外性质研究[D].河北医科大学,2009:
  • 3Chou TH,Chen SC,Chu IM. Effect of composition on the sta- bility of liposomal irinotecan prepared by a pH gradient method [J]. J Biosci Bioeng, 2003, 95(4): 405-408. 被引量:1
  • 4Daryl C. Drummond, Charles O. Noble, Zexiong Guo, etal. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy[J]. Cancer Res , 2006, 66(6): 3271-3277. 被引量:1
  • 5Hiraku Onishi, Yoshiaki Maehida, Yoshiharu Machida. Anti- tumor properties irinoteeawcontaining nanoparticles prepared using Poly (DL lactic acid) and Poly(ethylene glycol)-block- poly(propy leneglyeol)-block-poly(ethylene glycol) [J]. Biol Pharm Bull, 2003, 26(1): 116 119. 被引量:1
  • 6刘玉梅..长春碱纳米粒的制备及其抗肿瘤作用的实验研究[D].西北农林科技大学,2009:
  • 7张炎,鲁功成.阿霉素纳米粒逆转P-gp介导的膀胱移行细胞癌多药耐药的实验研究[J].临床泌尿外科杂志,2003,18(3):167-169. 被引量:7
  • 8Zhang P, Ling G, Pan X, et al. Novel nanostructured lipid dextran sulfate hybrid carriers overcome tumor muhidrug re sistance of mitoxantrone hydrochloride [J]. Nanomedicine, 2012, 8(2):185 193. 被引量:1
  • 9Zhang P,Ling G,Sun J, et al. Multifunetional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated el? ux [J]. Biomaterials, 2011,32(23) : 5524-5533. 被引量:1
  • 10王冬梅,马焱鑫.微柱离心-HPLC法测定盐酸伊立替康脂质体包封率[J].航空航天医学杂志,2011,22(4):454-455. 被引量:2

二级参考文献42

共引文献55

同被引文献44

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部